Identical twin toddlers who presented with severe arthritis helped scientists to identify the first gene mutation that can single-handedly cause a juvenile form of this inflammatory joint disease. By investigating the DNA of individual blood cells of both children and then modelling the genetic defect in a mouse model, the research team led by Adrian Liston (VIB-KU Leuven) was able to unravel the disease mechanism. The findings may help to develop an appropriate treatment as well.
Juvenile idiopathic arthritis is the most common form of all childhood rheumatic diseases. It is defined as arthritis that starts at a young age and persists throughout adulthood, but which does not have a defined cause. Patients present with a highly variable clinical picture, and scientists have long suspected that different combinations of specific genetic susceptibilities and environmental triggers drive the disease.
A single gene mutation
In a new study by researchers at VIB, KU Leuven and UZ Leuven, the cause of juvenile arthritis in a young pair of identical twins was traced back to a single genetic mutation.
“Single-cell sequencing let us track what was going wrong in every cell type in the twin’s blood, creating a link from genetic mutation to disease onset,” explains Dr. Stephanie Humblet-Baron (VIB-KU Leuven), one of the researchers involved in the study. “It was the combination of next generation genetics and immunology approaches that allowed us to find out why these patients were developing arthritis at such a young age.”
Modelling a human disease in mice
Parallel studies in mice confirmed that the gene defect found in the patients’ blood cells indeed led to an enhanced susceptibility to arthritis. Prof. Susan Schlenner (VIB-KU Leuven), first author of the study, stresses the relevance of this approach: “New genetic editing approaches bring mouse research much closer to the patient. We can now rapidly produce new mouse models that reproduce human mutations in mice, allowing us to model the disease of individual patients.”
According to immunology prof. Adrian Liston (VIB-KU Leuven) such insights prove invaluable in biomedical research: “Understanding the cause of the disease unlocks the key to treating the patient.”
From cause to cure
Liston’s team collaborated closely with prof. Carine Wouters (UZ Leuven), who coordinated the clinical aspect of the research: “The identification of a single gene that can cause juvenile idiopathic arthritis is an important milestone. A parallel mouse model with the same genetic mutation is a great tool to dissect the disease mechanism in more detail and to develop more effective targeted therapies for this condition.”
And the young patients? They are relieved to know that scientists found the cause of their symptoms: “We are delighted to know that an explanation has been found for our illness and more so because we are sure it will help other children.”
Thankfully, the youngsters’ arthritis is under good control at th?e moment. Thanks to the new scientific findings, their doctors will be in a much better position to treat any future flare-ups.
The Latest on: Juvenile idiopathic arthritis
via Google News
The Latest on: Juvenile idiopathic arthritis
- Jingle Bell Run in Perrysburg will raise critical funding for the Arthritis Foundationon December 2, 2021 at 5:27 pm
Arthritis affects tens of millions of Americans. According to the Arthritis Foundation, it is the number one cause of disability in this country. An upcoming event in Perrysburg is aimed at helping ...
- Your Holiday Gift Guide for Spoonies, by Spoonieson November 30, 2021 at 7:40 am
Gift ideas from seven small businesses run by people living with chronic conditions to make this holiday season even more festive.
- ‘She’s been through hell and back’: young rider takes on illness and beats bullies to run successful businesson November 28, 2021 at 10:52 am
A young rider who had to give up her dream of professional showjumping owing to a long-term medical condition has set up a thriving business — and may be helping inspire others along the way. Grace ...
- Why Are Girls Are More Prone To Juvenile Rheumatoid Arthritis?on November 26, 2021 at 6:05 am
Do you know that even kids are prone to developing arthritis? As shocking as it sounds, it's true. Children can develop Juvenile Idiopathic Arthritis (JIA), also known as Juvenile Rheumatoid Arthritis ...
- Rheumatic Disease and COVID Risks, Outcomes: Clinical Takeawayson November 23, 2021 at 4:17 pm
Current data on COVID risk in people with psoriatic arthritis and rheumatoid arthritis. Key clinical takeaways on outcomes and immunosuppressant drugs from rheumatologist and clinical pharmacist ...
- Secukinumab Reduces Flare Risk in Juvenile PsA and ERAon November 23, 2021 at 11:00 am
Secukinumab (Cosentyx) was effective in treating children and adolescents with psoriatic arthritis (PsA) and enthesitis-related arthritis (ERA), resulting in a significantly longer time to flare ...
- American College of Rheumatology, Nov. 3-9on November 22, 2021 at 9:01 pm
The annual meeting of the American College of Rheumatology was held virtually this year from Nov. 3 to 9 and attracted participants from around the world, including rheumatology specialists, ...
- Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritison November 19, 2021 at 7:33 am
Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti–interleukin-1β ...
- Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitison November 18, 2021 at 10:39 am
and active polyarticular juvenile idiopathic arthritis (JIA) and juvenile psoriatic arthritis (PsA) in patients two years of age and older who have responded inadequately to previous therapy with ...
- Early Biologics Better in Juvenile Idiopathic Arthritison November 8, 2021 at 9:00 am
For patients with polyarticular juvenile idiopathic arthritis (JIA), a strategy of using early combination therapy led to better outcomes than a traditional step-up approach or initial biologic ...
via Bing News